Ad-hoc | 23 January 2009 19:30
ECKERT & ZIEGLER Strahlen- und Medizintechnik AG / Acquisition
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Berlin, 23.1.2009 – The Berlin based Eckert & Ziegler Strahlen- und
Medizintechnik AG (ISIN DE0005659700) has exercised its option acquired in
December 2008 and taken over all shares of the Braunschweig, Germany, based
company nuclitec GmbH and its French and US based sister companies nuclitec
sarl and nuclitec Inc. (together see: www.nuclitec.com). The purchase price
agreed on for the companies and for the cash reserves remaining in the
companies was 6.6 million EUR. A capital increase is currently being
implemented to partly finance the transaction.
The long-established isotope specialist nuclitec used to trade under the
names of QSA Global GmbH and QSA Global sarl and counts worldwide among the
most established companies in the sector. It has been producing radioactive
components for the medical and measurement engineering field for over 30
years. In the last fiscal year that ended on 31.3.2008, the turnover
amounted to 23.1 million EUR. About 120 employees thereby achieved an
approximately balanced result (plus 0.1 million EUR).
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
Dr. Andreas Eckert, CEO of Eckert & Ziegler, commented: 'nuclitec and
Eckert & Ziegler complement each other perfectly. They have considerable
synergy potential when manufacturing and selling isotope components for
industrial, scientific and medical applications. In order to increase
profitability, we will during the next months need to implement a number of
structural changes, but Braunschweig itself as a production site will
remain. We look forward to welcome the talents and the experience that the
nuclitec staff brings to our group. Also, we are excited about the
interesting future fields of activity that nuclitec will contribute, in
particular the clean-room manufacturing of the radiopharmaceutical
Yttrium-90 and the environmental services.'
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, D-13125 Berlin
Tel.: +49 (0) 30 / 94 10 84-138, Fax -112
E-Mail: karolin.riehle@ezag.de, www.ezag.de
23.01.2009 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: ECKERT & ZIEGLER Strahlen- und Medizintechnik AG
Robert-Rössle-Str. 10
13125 Berlin
Deutschland
Phone: +49 (0)30 941 084-0
Fax: +49 (0)30 941 084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Listed: Regulierter Markt in Frankfurt (Prime Standard), Stuttgart;
Freiverkehr in Berlin, München, Hamburg, Düsseldorf
End of News DGAP News-Service
---------------------------------------------------------------------------